![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, April 27, 2023 12:23:18 PM
There is discussion in the stem cell field about what product will be best for treating different disease indications- MSCs or their exosomes? There are pros and cons to each product, and one might be better than the other for the treatment of specific diseases or tissue injuries. For instance, exosomes might replace the functions of IV-administered MSCs for treating Graft vs. Host disease or for other immunomodulatory functions, whereas for tissue or bone repair MSCs injected locally and engineered to be retained for longer periods of time might be best, to orchestrate healing.
https://academic.oup.com/stmcls/pages/call-for-papers?login=false
![Bullish](/static/images/ih2-bull.png)
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM